Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

CAR T Cell Therapy for Solid Tumors.

Newick K, O'Brien S, Moon E, Albelda SM.

Annu Rev Med. 2017 Jan 14;68:139-152. doi: 10.1146/annurev-med-062315-120245. Epub 2016 Nov 17. Review.

PMID:
27860544
2.

Ubiquitin-specific Protease-7 Inhibition Impairs Tip60-dependent Foxp3+ T-regulatory Cell Function and Promotes Antitumor Immunity.

Wang L, Kumar S, Dahiya S, Wang F, Wu J, Newick K, Han R, Samanta A, Beier UH, Akimova T, Bhatti TR, Nicholson B, Kodrasov MP, Agarwal S, Sterner DE, Gu W, Weinstock J, Butt TR, Albelda SM, Hancock WW.

EBioMedicine. 2016 Nov;13:99-112. doi: 10.1016/j.ebiom.2016.10.018. Epub 2016 Oct 15.

3.

Chimeric antigen receptor T-cell therapy for solid tumors.

Newick K, Moon E, Albelda SM.

Mol Ther Oncolytics. 2016 Apr 13;3:16006. doi: 10.1038/mto.2016.6. eCollection 2016. Review.

4.

Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization.

Newick K, O'Brien S, Sun J, Kapoor V, Maceyko S, Lo A, Puré E, Moon E, Albelda SM.

Cancer Immunol Res. 2016 Jun;4(6):541-51. doi: 10.1158/2326-6066.CIR-15-0263. Epub 2016 Apr 4.

5.

A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors.

Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S, Newick K, Lo A, June CH, Zhao Y, Moon EK.

Cancer Res. 2016 Mar 15;76(6):1578-90. doi: 10.1158/0008-5472.CAN-15-2524.

6.

HDAC5 controls the functions of Foxp3(+) T-regulatory and CD8(+) T cells.

Xiao H, Jiao J, Wang L, O'Brien S, Newick K, Wang LC, Falkensammer E, Liu Y, Han R, Kapoor V, Hansen FK, Kurz T, Hancock WW, Beier UH.

Int J Cancer. 2016 May 15;138(10):2477-86. doi: 10.1002/ijc.29979. Epub 2016 Jan 19.

7.

Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.

Moon EK, Ranganathan R, Eruslanov E, Kim S, Newick K, O'Brien S, Lo A, Liu X, Zhao Y, Albelda SM.

Clin Cancer Res. 2016 Jan 15;22(2):436-47. doi: 10.1158/1078-0432.CCR-15-1070. Epub 2015 Aug 31.

8.

Disabling Mitochondrial Peroxide Metabolism via Combinatorial Targeting of Peroxiredoxin 3 as an Effective Therapeutic Approach for Malignant Mesothelioma.

Cunniff B, Newick K, Nelson KJ, Wozniak AN, Beuschel S, Leavitt B, Bhave A, Butnor K, Koenig A, Chouchani ET, James AM, Haynes AC, Lowther WT, Murphy MP, Shukla A, Heintz NH.

PLoS One. 2015 May 26;10(5):e0127310. doi: 10.1371/journal.pone.0127310. eCollection 2015.

9.

Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells.

Lo A, Wang LS, Scholler J, Monslow J, Avery D, Newick K, O'Brien S, Evans RA, Bajor DJ, Clendenin C, Durham AC, Buza EL, Vonderheide RH, June CH, Albelda SM, Puré E.

Cancer Res. 2015 Jul 15;75(14):2800-2810. doi: 10.1158/0008-5472.CAN-14-3041. Epub 2015 May 15.

10.

Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors.

Wang E, Wang LC, Tsai CY, Bhoj V, Gershenson Z, Moon E, Newick K, Sun J, Lo A, Baradet T, Feldman MD, Barrett D, Puré E, Albelda S, Milone MC.

Cancer Immunol Res. 2015 Jul;3(7):815-26. doi: 10.1158/2326-6066.CIR-15-0054. Epub 2015 May 4.

11.

Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients.

Stevenson JP, Kindler HL, Papasavvas E, Sun J, Jacobs-Small M, Hull J, Schwed D, Ranganathan A, Newick K, Heitjan DF, Langer CJ, McPherson JM, Montaner LJ, Albelda SM.

Oncoimmunology. 2013 Aug 1;2(8):e26218. Epub 2013 Aug 27.

12.

Mitochondrial-targeted nitroxides disrupt mitochondrial architecture and inhibit expression of peroxiredoxin 3 and FOXM1 in malignant mesothelioma cells.

Cunniff B, Benson K, Stumpff J, Newick K, Held P, Taatjes D, Joseph J, Kalyanaraman B, Heintz NH.

J Cell Physiol. 2013 Apr;228(4):835-45. doi: 10.1002/jcp.24232.

13.

Peroxiredoxin 3 is a redox-dependent target of thiostrepton in malignant mesothelioma cells.

Newick K, Cunniff B, Preston K, Held P, Arbiser J, Pass H, Mossman B, Shukla A, Heintz N.

PLoS One. 2012;7(6):e39404. doi: 10.1371/journal.pone.0039404. Epub 2012 Jun 25.

14.

Non-specific DNA binding interferes with the efficient excision of oxidative lesions from chromatin by the human DNA glycosylase, NEIL1.

Odell ID, Newick K, Heintz NH, Wallace SS, Pederson DS.

DNA Repair (Amst). 2010 Feb 4;9(2):134-43. doi: 10.1016/j.dnarep.2009.11.005. Epub 2009 Dec 11. Erratum in: DNA Repair (Amst). 2010 Aug 5;9(8):938.

Supplemental Content

Loading ...
Support Center